Eduardo Bravo MBA

Eduardo Bravo joined LSP as a Partner in 2021. He is the CEO of EBAC (European Biotech Acquisition Corporation), a Nasdaq’s listed SPAC sponsored by LSP with a focus on European biotech companies.

Eduardo has over 25 years of senior management and board experience in the biopharmaceutical sector, having held the position of CEO at Nordic Nanovector, TiGenix, and Celebrex. As CEO at TiGenix, he oversaw several financing rounds, the company’s IPO on Nasdaq, and its eventual acquisition by Takeda. Earlier in his career, Eduardo held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He is currently Chairman of the Board at Vivet Therapeutics and Engitix Ltd, and a Board Member at Sutura Therapeutics. Eduardo was President of the European Biopharmaceutical Enterprises Board of Directors between 2016 and 2018 and was also a member of the Executive Committee of the Alliance for Regenerative Medicine.

He holds a degree in Business Administration and an MBA from INSEAD.